Research.Patient.info

Advanced/metastatic gynecological cancer overexpressing FGFR2b research hub

1 indexed studies · 0 currently recruiting

ongoing, recruitingPhase I and Phase II (Integrated)- Other
Trail aiming to assess the safety and clinical activity of bemarituzumab + bevacizumab in advanced/metastatic gynecological cancer overexpressing FGFR2b
This study is testing a new combination of medicines, bemarituzumab and bevacizumab, for women with advanced gynaecological cancer. Doctors want to see if this treatment is safe and helps people whose cancer has a specific protein called FGFR2b.
France